Not AWRW. I am in ARWR that's not my point the point is another Hematologic company. Private or Public. Acerta Pharma has ACP-196 which will put PCYC in dust when APC 196 is approved. Try AGIO, ARIA, BLUE, KITE, TGTX, and even ARGS.. Imbruvica is all news. Its good they are partnering but they need to buy outright in order to strengthen their pipeline. GET A CLUE. PCYC can and will tank like GILD cuz of HEP C competition. Catch my drift or are you like Bob Duggan clueless.
Like our President Robert Duggan is in over his head. All he is doing is selling a successful drug with all these agreements. He can't strike out on his own. Hence this drug will run its course an get replaced by alternative drugs in development or approved. This is happening to the big pharma GILD. Expand your business product depth Robert. Get a clue.
when some large pharma takes this over litigation will even go on more years. This is so pathetic. All because of a dosage issue. How sad. GLTA. Hold this and u will be rewarded.
This will far surpass PCYC Ibrutinib. I am a gonna just sit on this until my last days on earth. GLTA
Then all those Hedge Funds can make suckers out of those who sell how sad. So manipulating. This is so un American but oh well GREED kills. GREED also pays taxes for those who lose so in the end we all lose.
I have seen this occur in the past to other companies, just sit tight. YMI Sciences acted the same way then GILD took it over. YMI Sciences developed BITE technology and Idealilsib from this.
will be thrown out. Since those clowns went for pennies on the dollar for damages and the remaining holders will be amply rewarded.
ARWR is a classic buyout for any Large HEP B companany ie GILD. Just be patient. ARWR juar needs to be open to a reasonable offer.
Stein described one patient to me, a woman in her late sixties with A.M.L. She had already undergone a bone-marrow transplant, had relapsed, and then had more chemotherapy; nothing helped. To Stein’s surprise, after three months on AG-221, her leukemia had gone into complete remission and her blood count had returned to normal. “It was transformative,” Stein said. “She gained weight and told me that the pep in her step was back.” Another patient, a sixty-year-old man with A.M.L., also had failed to benefit from several regimens of chemotherapy, and he, too, went into remission after taking AG-221. Moreover, the side effects of the medication, which is given orally, have been manageable—mostly mild nausea and a loss of appetite. In April, Stein presented his findings to a packed auditorium at the annual meeting of the American Association for Cancer Research, in San Diego. It was the first public airing of the results of AG-221; patients with progressive A.M.L. had never improved so quickly and definitively. “These data signal the first real advance for A.M.L. in thirty years,” Stephen Nimer, the director of the Sylvester Comprehensive Cancer Center, at the University of Miami, and an eminent leukemia researcher and clinician, told me. “It’s a huge step forward.” Most cancers, once they spread, are incurable. Cancer researchers are desperate to raise the number of patients who go into remission, to prolong those remissions, and to ultimately prevent relapse. So when a new way of attacking cancer comes along, it is often greeted with incautious euphoria and an assumption that the new paradigm can be quickly converted into a cure for all cancers. Agios hopes that AG-221 will become a key in treating those cancers which are driven by IDH-2. In March, the company launched clinical trials of another drug, AG-120, which targets a different mutated enzyme, IDH-1. The mutation occurs in as many as ten per cent of A.M.L. patients, but it’s also found in seventy per cent of patients with a type of brain tumor called a glioma and in fifty per cent of cases of cancer of the cartilage. The treatment of cancer, which traditionally adopted a destroy-the-village strategy, is becoming ever more like precision warfare. “We treat people with the specific mutation who may benefit,” David Schenkein, the C.E.O. of Agios, told me.
SAN DIEGO — A first-in-class compound has shown activity in patients with advanced and refractory blood cancers.
Initial results with AG-221, a novel IDH2 mutant inhibitor (under development by Agios), were presented here at the at the American Association for Cancer Research 2014. The early data show that AG-221 is well tolerated, and that clinical and pharmacodynamic activity in patients with relapsed and refractory IDH2-mutant hematologic malignancies, mostly acute myeloid leukemia (AML), is promising. The effect was observed even in patients who received the lowest dose.
Of the 7 evaluable patients, 5 achieved complete remission or complete remission with incomplete platelet count recovery, which was defined as clearance of blast cells from the bone marrow and a platelet count not exceeding 100,000. Six of the 7 patients had an objective response.
"This kind of data is unheard of," said lead author Eytan M. Stein, MD, assistant attending physician in the leukemia service at the Memorial Sloan-Kettering Cancer Center in New York City. Some of the patients in the study had relapsed after bone marrow transplantation; in these patients, survival is typically very poor, he explained. "These are extremely exciting results."
The primary goal of this phase 1 study was to determine the safety and tolerability of AG-221. Dr. Stein noted that the research team was pleased to find promising clinical activity in patients with AML and IDH2 mutations.
This is early but it appears that mutant IDH2 is targetable, said John C. Byrd, MD, professor of medicine at Ohio State University Comprehensive Cancer Center in Columbus. "What impressed me is that the agent seems to be very patient-friendly, and it would make sense to move it into
Its going to go where it wants to so just take advantage of the situation and average cost your price.
I view any drop in price as a buying oppty. Not many oppty's occur like this so I am holding long and strong.
Sit this whole freekshow out until the opportunists make money and the slugs lose there #$%$ in unnecessary market drops. GLTA
Agree it will rise about 8 bucks today. Hold steady until a suitor arrives to bring ARC 520 to success. This is what my tea leaves say. Cheap company with lotsa potential upside. GLTA. Lock in your losses and sell if you want..
GILD bought MITI Micromet under the same scenario and developed Idealilsilib. Now look that one up. ARWR is a HEP B drug company whose drug actually works. Put that monotherapy with GILD's drug and we surely will get a deal. This can happen GILD can absorb this childs play loss and come out a winner in the end. GLTA
monotherapy alone wont' work so no big deal. mix drugs and get a bigger impact. Look for a partnership. Micromet was like that when GILD bought them out. to form Idealilsililb
Arrowhead reported on a phase-two study of ARC-520 for hepatitis B in two different doses. The one-milligram dose induced a 39% reduction in the virus' surface antigen (used to measure its presence in the body), while the two-milligram dose induced a 51% reduction.
RBC Capital Markets analyst Michael Yee wrote in a research note that this result was "on the low end of expectations" and "lowers investor confidence that cures will occur as a monotherapy." (Monotherapy is the use of a single drug rather than a combination.) Data on the three-milligram study is expected next year.
"We spoke to company — they are still optimistic on dose response and believe less 'variability' and tighter/narrower ranges as you go up in dose," Yee wrote.
Would be foolish to sell after this overdone selloff.
ARWR is the kind of company a large pharma wants. I am holding no reason to sell on a bunch of bs spewed by shorts w/no factual backup. GLTA. It's frustrating but u need balls to invest in this sort of market.
before the big boys to. AGIO, ARWR, TGTX, BLUE, TKAI and the like. Otherwise Ibrutinib/Imbruvica will just be out done by the therapies that will be far superior than their technology. Not actively looking for growth companies will kill PCYC and the stock price will reflect it as she declines. GLTA